Initial Results of Efficacy and Safety of Sofosbuvir Among Pakistani Population: A Real Life Trial - Hepatitis Eradication Accuracy Trial of Sofosbuvir (HEATS)

Overview

Journal Pak J Med Sci

Specialty General Medicine

Date 2017 Apr 4

PMID 28367171

Citations 4

Authors

Zahid Azam

Muhammad Shoaib

Masood Javed

Muhammad Adnan Sarwar

Hafeezullah Shaikh

Nasir Khokhar

Affiliations

Soon will be listed here.

Abstract

Objective: The uridine nucleotide analogue sofosbuvir is a selective inhibitor of hepatitis C virus (HCV) NS5B polymerase approved for the treatment of chronic HCV infection with genotypes 1 - 4. The objective of the study was to evaluate the interim results of efficacy and safety of regimens containing Sofosbuvir (Zoval) among Pakistani population with the rapid virologic response (RVR2/4 weeks) with HCV infections.

Methods: This is a multicenter open label prospective observational study. Patients suffering from chronic Hepatitis C infection received Sofosbuvir (Zoval) 400 mg plus ribavirin (with or without peg interferon) for 12/24 weeks. The interim results of this study were rapid virological response on week 4. Data was analyzed using SPSS version 21 for descriptive statistics.

Results: A total of 573 patients with HCV infection were included in the study. The mean age of patients was 46.07 ± 11.41 years. Out of 573 patients 535 (93.3%) were treatment naive, 26 (4.5%) were relapser, 7 (1.2%) were non-responders and 5 (1.0%) were partial responders. A rapid virologic response was reported in 563(98.2%) of patients with HCV infection after four weeks of treatment. The treatment was generally well tolerated.

Conclusion: Sofosbuvir (Zoval) is effective and well tolerated in combination with ribavirin in HCV infected patients.

Citing Articles

End Treatment Response and Sustained Viral Response in Patients With Hepatitis C Virus Receiving Sofosbuvir and Daclatasvir.

Rahman A, Amir M, Jamal Q, Riaz M, Fareed K, Siddiqui M Cureus. 2023; 15(5):e38833.

PMID: 37303399 PMC: 10253241. DOI: 10.7759/cureus.38833.

Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan.

Mafirakureva N, Lim A, Khalid G, Aslam K, Campbell L, Zahid H J Viral Hepat. 2020; 28(2):268-278.

PMID: 33051950 PMC: 7821258. DOI: 10.1111/jvh.13422.

Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan.

Khaliq S, Raza S Medicina (Kaunas). 2018; 54(5).

PMID: 30400604 PMC: 6262417. DOI: 10.3390/medicina54050080.

Rapid virological&End treatment response of patients treated with Sofosbuvir in Chronic Hepatitis C.

Siddique M, Shoaib S, Saad A, Iqbal H, Durrani N Pak J Med Sci. 2017; 33(4):813-817.

PMID: 29067045 PMC: 5648944. DOI: 10.12669/pjms.334.12785.

References

Lam A, Murakami E, Espiritu C, Micolochick Steuer H, Niu C, Keilman M . PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother. 2010; 54(8):3187-96. PMC: 2916354. DOI: 10.1128/AAC.00399-10. View

Williams I, Bell B, Kuhnert W, Alter M . Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med. 2011; 171(3):242-8. DOI: 10.1001/archinternmed.2010.511. View

Kowdley K, Lawitz E, Crespo I, Hassanein T, Davis M, DeMicco M . Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013; 381(9883):2100-7. DOI: 10.1016/S0140-6736(13)60247-0. View

Chung R . A watershed moment in the treatment of hepatitis C. N Engl J Med. 2012; 366(3):273-5. DOI: 10.1056/NEJMe1113272. View

Lavanchy D . Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2010; 17(2):107-15. DOI: 10.1111/j.1469-0691.2010.03432.x. View

Razali K, Thein H, Bell J, Cooper-Stanbury M, Dolan K, Dore G . Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend. 2007; 91(2-3):228-35. DOI: 10.1016/j.drugalcdep.2007.05.026. View

Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon S . Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368(20):1878-87. DOI: 10.1056/NEJMoa1214853. View

Hamid S, Umar M, Alam A, Siddiqui A, Qureshi H, Butt J . PSG consensus statement on management of hepatitis C virus infection--2003. J Pak Med Assoc. 2004; 54(3):146-50. View

Rodriguez-Torres M, Lawitz E, Kowdley K, Nelson D, DeJesus E, McHutchison J . Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol. 2012; 58(4):663-8. DOI: 10.1016/j.jhep.2012.11.018. View

10.

Muir A, Provenzale D . A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol. 2002; 34(3):268-71. DOI: 10.1097/00004836-200203000-00015. View

11.

Gane E, Stedman C, Hyland R, Ding X, Svarovskaia E, Symonds W . Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013; 368(1):34-44. DOI: 10.1056/NEJMoa1208953. View

12.

. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015; 63(1):199-236. DOI: 10.1016/j.jhep.2015.03.025. View

13.

Lavanchy D . The global burden of hepatitis C. Liver Int. 2009; 29 Suppl 1:74-81. DOI: 10.1111/j.1478-3231.2008.01934.x. View

14.

Jacobson I, Gordon S, Kowdley K, Yoshida E, Rodriguez-Torres M, Sulkowski M . Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013; 368(20):1867-77. DOI: 10.1056/NEJMoa1214854. View

15.

Lawitz E, Lalezari J, Hassanein T, Kowdley K, Poordad F, Sheikh A . Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013; 13(5):401-8. DOI: 10.1016/S1473-3099(13)70033-1. View

16.

Alter M, Nainan O, McQuillan G, Gao F, Moyer L, Kaslow R . The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999; 341(8):556-62. DOI: 10.1056/NEJM199908193410802. View

17.

Delarocque-Astagneau E, Meffre C, Dubois F, Pioche C, Le Strat Y, Roudot-Thoraval F . The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat. 2009; 17(6):435-43. DOI: 10.1111/j.1365-2893.2009.01196.x. View

18.

Duberg A, Janzon R, Back E, Ekdahl K, Blaxhult A . The epidemiology of hepatitis C virus infection in Sweden. Euro Surveill. 2008; 13(21). DOI: 10.2807/ese.13.21.18882-en. View

19.

Waheed Y, Shafi T, Safi S, Qadri I . Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors. World J Gastroenterol. 2009; 15(45):5647-53. PMC: 2789216. DOI: 10.3748/wjg.15.5647. View

20.

Sofia M, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S . Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 2010; 53(19):7202-18. DOI: 10.1021/jm100863x. View